AC   CVCL_2186
DR   CLO; CLO_0008973
DR   EFO; EFO_0006750
DR   ArrayExpress; E-MTAB-2706
DR   Cell_Model_Passport; SIDM00028
DR   CLS; 300445/p505_SCLC-22H
DR   DepMap; ACH-001386
DR   DSMZ; ACC-373
DR   GEO; GSM784218
DR   PharmacoDB; SCLC22H_1362_2019
DR   Progenetix; CVCL_2186
DR   Wikidata; Q54952445
RX   PubMed=1320893;
RX   PubMed=1845952;
RX   PubMed=2438285;
RX   PubMed=2473086;
RX   PubMed=3029138;
RX   PubMed=11414198;
RX   PubMed=25485619;
RX   PubMed=25960936;
CC   Doubling time: 75-85 hours, depending on growth medium (PubMed=3029138); 75 hours (PubMed=2438285); ~48 hours (DSMZ).
CC   HLA typing: A*01:01,32:01; B*35:86,27:05; C*02:02,02:02 (PubMed=25960936).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Arg (c.833C>G); ClinVar=VCV000376644; Zygosity=Homozygous (DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: SNP array analysis.
CC   Derived from metastatic site: Pericardial effusion.
ST   Source(s): CLS; DepMap; DSMZ
ST   Amelogenin: X,Y
ST   CSF1PO: 10
ST   D13S317: 12
ST   D16S539: 12
ST   D18S51: 14,15
ST   D21S11: 29,31.2
ST   D3S1358: 15
ST   D5S818: 11,12
ST   D7S820: 11
ST   D8S1179: 12,13
ST   FGA: 22 (CLS)
ST   FGA: 22,23 (DepMap)
ST   Penta D: 9
ST   Penta E: 12,13
ST   TH01: 9.3
ST   TPOX: 8,9
ST   vWA: 17
DI   NCIt; C4917; Lung small cell carcinoma
DI   ORDO; Orphanet_70573; Small cell lung cancer
OX   NCBI_TaxID=9606; ! Homo sapiens
OI   CVCL_0024 ! SCLC-21H
SX   Male
AG   46Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 20-05-21; Version: 27
RX   PubMed=1320893; DOI=10.1159/000163712;
RA   Verbeeck M.A.E., Elands J.P.M., de Leij L.F.M.H., Buys C.H.C.M.,
RA   Carney D.N., Bepler G., Roebroek A.J.M., van de Ven W.J.M.,
RA   Burbach J.P.H.;
RT   "Expression of the vasopressin and gastrin-releasing peptide genes in
RT   small cell lung carcinoma cell lines.";
RL   Pathobiology 60:136-142(1992).
RX   PubMed=1845952; DOI=10.1002/1097-0142(19910201)67:3<619::AID-CNCR2820670317>3.0.CO;2-Y;
RA   Broers J.L.V., Mijnheere E.P., Rot M.K., Schaart G., Sijlmans A.,
RA   Boerman O.C., Ramaekers F.C.S.;
RT   "Novel antigens characteristic of neuroendocrine malignancies.";
RL   Cancer 67:619-633(1991).
RX   PubMed=2438285; DOI=10.1007/BF00396382;
RA   Bepler G., Jaques G., Koehler A., Gropp C., Havemann K.;
RT   "Markers and characteristics of human SCLC cell lines. Neuroendocrine
RT   markers, classical tumor markers, and chromosomal characteristics of
RT   permanent human small cell lung cancer cell lines.";
RL   J. Cancer Res. Clin. Oncol. 113:253-259(1987).
RX   PubMed=2473086; DOI=10.1242/jcs.91.1.91;
RA   Broers J.L.V., Rot M.K., Oostendorp T., Bepler G., de Leij L.F.M.H.,
RA   Carney D.N., Vooijs G.P., Ramaekers F.C.S.;
RT   "Spontaneous changes in intermediate filament protein expression
RT   patterns in lung cancer cell lines.";
RL   J. Cell Sci. 91:91-108(1988).
RX   PubMed=3029138; DOI=10.1007/BF00389964;
RA   Bepler G., Jaques G., Neumann K., Aumuller G., Gropp C., Havemann K.;
RT   "Establishment, growth properties, and morphological characteristics
RT   of permanent human small cell lung cancer cell lines.";
RL   J. Cancer Res. Clin. Oncol. 113:31-40(1987).
RX   PubMed=11414198; DOI=10.1007/s004320000207;
RA   Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H.,
RA   Wolf E., Gabius H.J.;
RT   "Comprehensive galectin fingerprinting in a panel of 61 human tumor
RT   cell lines by RT-PCR and its implications for diagnostic and
RT   therapeutic procedures.";
RL   J. Cancer Res. Clin. Oncol. 127:375-386(2001).
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).